BUSINESS BRIEFING / PHARMACEUTICALS
- Share via
Allergan Inc.’s promotions for the eyelash-growing drug Latisse are “misleading” because they don’t describe safety risks, regulators said.
The Food and Drug Administration cited the website www.latisse.com and a placard with a timeline of the product’s introduction in a warning letter to the Irvine company.
Allergan says the timeline is no longer being used.
Materials promoting a drug’s benefits must also address its risks, which in this case include allergic reactions or hair growth outside the treatment area, the FDA said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
